ifosfamide has been researched along with Leiomyosarcoma in 53 studies
Leiomyosarcoma: A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide." | 9.14 | Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. ( Baker, LH; Blay, JY; Chawla, SP; Demetri, GD; Elsayed, YA; Gómez, J; Hande, KR; Izquierdo, MA; Keohan, ML; Le Cesne, A; Lebedinsky, C; Park, YC; Ritch, P; Samuels, BL; Schuetze, S; von Mehren, M, 2009) |
| "The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 9.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
| "This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy." | 9.08 | Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996) |
| "Ifosfamide is an active chemotherapeutic agent in the treatment of soft tissue sarcoma." | 9.07 | Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. ( Baker, LH; Blair, SC; Zalupski, MM, 1994) |
| "Ifosfamide is metabolized into chloroacetaldehyde, which can cause acute kidney injury." | 8.12 | Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report. ( Boskabadi, J; Salehifar, E; Yousefi-Mazhin, E, 2022) |
| "To assess the impact of different factors on response rate (RR), time to tumor progression (TTP), and overall survival time (OS) in patients with locally advanced or metastatic soft tissue sarcoma (ASTS), included in three protocols with high-dose ifosfamide (HDIF)." | 7.72 | Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS). ( Balañá, C; Buesa, J; Casado, A; de Las Peñas, R; del Muro, XG; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Quintana, MJ, 2004) |
| "Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1." | 7.70 | Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000) |
| " In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy." | 7.70 | Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000) |
| "A 6-week-old infant with an incompletely resected cardiac leiomyosarcoma was treated postoperatively with ifosfamide and etoposide." | 7.69 | Successful treatment of a primary cardiac leiomyosarcoma with ifosfamide and etoposide. ( Amenta, P; Drachtman, RA; Ettinger, LJ; Han, P, 1996) |
| "The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy." | 7.68 | Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. ( Barrett, RJ; Blessing, JA; McGehee, R; Sutton, GP, 1992) |
| "Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7." | 5.28 | Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. ( Hawkins, RE; Mansi, JL; Wiltshaw, E, 1990) |
| "To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide." | 5.14 | Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. ( Baker, LH; Blay, JY; Chawla, SP; Demetri, GD; Elsayed, YA; Gómez, J; Hande, KR; Izquierdo, MA; Keohan, ML; Le Cesne, A; Lebedinsky, C; Park, YC; Ritch, P; Samuels, BL; Schuetze, S; von Mehren, M, 2009) |
| "The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 5.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
| "This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy." | 5.08 | Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996) |
| "Ifosfamide is an active chemotherapeutic agent in the treatment of soft tissue sarcoma." | 5.07 | Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. ( Baker, LH; Blair, SC; Zalupski, MM, 1994) |
| " Therefore, gemcitabine should be considered as the best option after doxorubicin failure in leiomyosarcoma patients." | 4.86 | [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines]. ( Bui-Nguyen, B; Italiano, A; Toulmonde, M, 2010) |
| "Ifosfamide is metabolized into chloroacetaldehyde, which can cause acute kidney injury." | 4.12 | Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report. ( Boskabadi, J; Salehifar, E; Yousefi-Mazhin, E, 2022) |
| "To assess the impact of different factors on response rate (RR), time to tumor progression (TTP), and overall survival time (OS) in patients with locally advanced or metastatic soft tissue sarcoma (ASTS), included in three protocols with high-dose ifosfamide (HDIF)." | 3.72 | Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS). ( Balañá, C; Buesa, J; Casado, A; de Las Peñas, R; del Muro, XG; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Quintana, MJ, 2004) |
| "Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1." | 3.70 | Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000) |
| " In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy." | 3.70 | Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000) |
| "A 6-week-old infant with an incompletely resected cardiac leiomyosarcoma was treated postoperatively with ifosfamide and etoposide." | 3.69 | Successful treatment of a primary cardiac leiomyosarcoma with ifosfamide and etoposide. ( Amenta, P; Drachtman, RA; Ettinger, LJ; Han, P, 1996) |
| "The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy." | 3.68 | Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. ( Barrett, RJ; Blessing, JA; McGehee, R; Sutton, GP, 1992) |
| "Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 2.67 | Gynecologic Oncology Group experience with ifosfamide. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990) |
| "Ifosfamide was ineffective as adjuvant chemotherapy and there was aggressive tumor growth while the patient was on this regimen." | 2.38 | Myxoid leiomyosarcoma of the uterus. ( d'Ablaing, G; Kunzel, KE; Mills, NZ; Muderspach, LI, 1993) |
| "Takayasu arteritis is a form of large vessel granulomatous vasculitis affecting often young or middle-aged women, especially of Asian descent." | 1.40 | Concomitant aortic leiomyosarcoma and takayasu arteritis in a 55-year-old male patient. ( Butrico, L; De Caridi, G; de Franciscis, S; Grande, R; Massara, M; Serra, R; Spinelli, F, 2014) |
| "Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7." | 1.28 | Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. ( Hawkins, RE; Mansi, JL; Wiltshaw, E, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.77) | 18.7374 |
| 1990's | 14 (26.42) | 18.2507 |
| 2000's | 14 (26.42) | 29.6817 |
| 2010's | 16 (30.19) | 24.3611 |
| 2020's | 7 (13.21) | 2.80 |
| Authors | Studies |
|---|---|
| Kunte, A | 1 |
| Patkar, S | 1 |
| Goel, M | 1 |
| Boskabadi, J | 1 |
| Yousefi-Mazhin, E | 1 |
| Salehifar, E | 1 |
| Miyazaki, C | 1 |
| Shiozawa, M | 1 |
| Koike, R | 1 |
| Ogihara, K | 1 |
| Sasaki, Y | 1 |
| Shiba, S | 1 |
| Nishida, S | 1 |
| Sakuragi, M | 1 |
| Mizunuma, H | 1 |
| Fujita, T | 1 |
| Fukushima, N | 1 |
| Lefor, AK | 1 |
| Kitayama, J | 1 |
| Sata, N | 1 |
| D'Ambrosio, L | 2 |
| Touati, N | 1 |
| Blay, JY | 4 |
| Grignani, G | 2 |
| Flippot, R | 1 |
| Czarnecka, AM | 1 |
| Piperno-Neumann, S | 2 |
| Martin-Broto, J | 2 |
| Sanfilippo, R | 1 |
| Katz, D | 1 |
| Duffaud, F | 2 |
| Vincenzi, B | 1 |
| Stark, DP | 1 |
| Mazzeo, F | 1 |
| Tuchscherer, A | 1 |
| Chevreau, C | 2 |
| Sherriff, J | 1 |
| Estival, A | 1 |
| Litière, S | 2 |
| Sents, W | 1 |
| Ray-Coquard, I | 2 |
| Tolomeo, F | 1 |
| Le Cesne, A | 3 |
| Rutkowski, P | 1 |
| Stacchiotti, S | 2 |
| Kasper, B | 1 |
| Gelderblom, H | 1 |
| Gronchi, A | 2 |
| Penel, N | 2 |
| Ryckewaert, T | 1 |
| Pannier, D | 1 |
| Squires, MH | 1 |
| Politano, S | 1 |
| Pollock, RE | 1 |
| Chen, JL | 1 |
| Grignol, V | 1 |
| Janopaul-Naylor, J | 1 |
| Kanter, KR | 1 |
| Flampouri, S | 1 |
| Nguyen, V | 1 |
| Olson, TA | 1 |
| Eaton, BR | 1 |
| Setola, E | 1 |
| Noujaim, J | 1 |
| Benson, C | 1 |
| Chawla, S | 1 |
| Palmerini, E | 1 |
| Jones, RL | 1 |
| Nakashima, K | 1 |
| Inatsu, H | 1 |
| Kitamura, K | 1 |
| Ter-Ovanesov, MD | 1 |
| Valkin, DL | 1 |
| Gaboyan, AS | 1 |
| Kukosh, MY | 1 |
| Ronzin, AV | 1 |
| Andrianova, VS | 1 |
| Larin, AL | 1 |
| Zhuk, AI | 1 |
| Mancari, R | 1 |
| Signorelli, M | 1 |
| Gadducci, A | 1 |
| Carinelli, S | 1 |
| De Ponti, E | 1 |
| Sesana, S | 1 |
| Corso, S | 1 |
| Chiappa, V | 1 |
| Colombo, N | 1 |
| Lissoni, AA | 1 |
| Sagara, K | 1 |
| Takayoshi, K | 1 |
| Kusumoto, E | 1 |
| Uchino, K | 1 |
| Matsumura, T | 1 |
| Kusaba, H | 1 |
| Momosaki, S | 1 |
| Ikejiri, K | 1 |
| Baba, E | 1 |
| Siurala, M | 1 |
| Bramante, S | 1 |
| Vassilev, L | 1 |
| Hirvinen, M | 1 |
| Parviainen, S | 1 |
| Tähtinen, S | 1 |
| Guse, K | 1 |
| Cerullo, V | 1 |
| Kanerva, A | 1 |
| Kipar, A | 1 |
| Vähä-Koskela, M | 1 |
| Hemminki, A | 1 |
| De Caridi, G | 1 |
| Butrico, L | 1 |
| Grande, R | 1 |
| Massara, M | 1 |
| Spinelli, F | 1 |
| de Franciscis, S | 1 |
| Serra, R | 1 |
| Hadoux, J | 1 |
| Rey, A | 2 |
| Duvillard, P | 2 |
| Lhommé, C | 2 |
| Balleyguier, C | 1 |
| Haie-Meder, C | 2 |
| Morice, P | 1 |
| Tazi, Y | 1 |
| Leary, A | 1 |
| Larue, C | 1 |
| Pautier, P | 2 |
| Schuler, M | 1 |
| Reichardt, P | 1 |
| Schönknecht, C | 1 |
| Hadjamu, M | 1 |
| Oechsner, M | 1 |
| Andratschke, N | 1 |
| Duma, MN | 1 |
| Fayette, J | 1 |
| Cupissol, D | 1 |
| Thyss, A | 1 |
| Guillemet, C | 2 |
| Rios, M | 1 |
| Rolland, F | 1 |
| Fargeot, P | 1 |
| Bay, JO | 1 |
| Mathoulin-Pelissier, S | 1 |
| Coindre, JM | 1 |
| Bui-Nguyen, B | 2 |
| Berretta, M | 1 |
| Zanet, E | 1 |
| Taibi, R | 1 |
| Martellotta, F | 1 |
| Pavone, P | 1 |
| Bearz, A | 1 |
| Gobitti, C | 1 |
| Ciancia, EM | 1 |
| Canzonieri, V | 1 |
| Tirelli, U | 1 |
| Demetri, GD | 1 |
| Chawla, SP | 1 |
| von Mehren, M | 1 |
| Ritch, P | 1 |
| Baker, LH | 2 |
| Hande, KR | 1 |
| Keohan, ML | 1 |
| Samuels, BL | 1 |
| Schuetze, S | 1 |
| Lebedinsky, C | 1 |
| Elsayed, YA | 1 |
| Izquierdo, MA | 1 |
| Gómez, J | 1 |
| Park, YC | 1 |
| Italiano, A | 1 |
| Toulmonde, M | 1 |
| Minobe, S | 1 |
| Todo, Y | 1 |
| Suzuki, Y | 1 |
| Aoyagi, Y | 1 |
| Umazume, T | 1 |
| Okamoto, K | 1 |
| Kato, H | 1 |
| Collins, IM | 1 |
| Thomas, DM | 1 |
| Ahn, JH | 1 |
| Mirza, T | 1 |
| Ameerally, P | 1 |
| Floquet, A | 1 |
| Gladieff, L | 1 |
| Bompas, E | 1 |
| Selle, F | 1 |
| Weber, B | 1 |
| Largillier, R | 1 |
| Bertucci, F | 1 |
| Opinel, P | 1 |
| Reynaud-Bougnoux, A | 1 |
| Delcambre, C | 1 |
| Isambert, N | 1 |
| Kerbrat, P | 1 |
| Netter-Pinon, G | 1 |
| Pinto, N | 1 |
| Ferrari, A | 1 |
| Collini, P | 1 |
| Casanova, M | 1 |
| Meazza, C | 1 |
| Podda, M | 1 |
| Mazza, EA | 1 |
| van Oosterom, AT | 1 |
| Mouridsen, HT | 1 |
| Nielsen, OS | 1 |
| Dombernowsky, P | 1 |
| Krzemieniecki, K | 1 |
| Judson, I | 2 |
| Svancarova, L | 1 |
| Spooner, D | 1 |
| Hermans, C | 2 |
| Van Glabbeke, M | 2 |
| Verweij, J | 2 |
| Fahn, W | 1 |
| Schlemmer, M | 1 |
| Issels, R | 1 |
| Uberfuhr, P | 1 |
| Reichart, B | 1 |
| Silvestris, N | 1 |
| Piscitelli, D | 1 |
| Crucitta, E | 1 |
| Fiore, M | 1 |
| De Lena, M | 1 |
| Lorusso, V | 1 |
| Maurel, J | 1 |
| Buesa, J | 1 |
| López-Pousa, A | 1 |
| del Muro, XG | 1 |
| Quintana, MJ | 1 |
| Martín, J | 1 |
| Casado, A | 1 |
| Martínez-Trufero, J | 1 |
| de Las Peñas, R | 1 |
| Balañá, C | 1 |
| Dusenbery, KE | 1 |
| Potish, RA | 1 |
| Argenta, PA | 1 |
| Judson, PL | 1 |
| Moreno Antón, F | 1 |
| Casado Herraez, A | 1 |
| Puente Vázquez, J | 1 |
| Gómez Díaz, R | 1 |
| Aragoncillo, P | 1 |
| Díaz-Rubio García, E | 1 |
| Canadyova, J | 1 |
| Setina, M | 1 |
| Smetanová, S | 1 |
| Mokracek, A | 1 |
| Sangster, G | 1 |
| Kaye, SB | 1 |
| Calman, KC | 1 |
| Dalton, JF | 1 |
| Dhote, R | 1 |
| Castagne, C | 1 |
| Zuber, M | 1 |
| Beuzeboc, P | 1 |
| Christoforov, B | 1 |
| Blair, SC | 1 |
| Zalupski, MM | 1 |
| Patterson, H | 1 |
| Gill, S | 1 |
| Fisher, C | 1 |
| Law, MG | 1 |
| Jayatilake, H | 1 |
| Fletcher, CD | 1 |
| Thomas, M | 1 |
| Grimer, R | 1 |
| Gusterson, BA | 1 |
| Cooper, CS | 1 |
| Kunzel, KE | 1 |
| Mills, NZ | 1 |
| Muderspach, LI | 1 |
| d'Ablaing, G | 1 |
| Han, P | 1 |
| Drachtman, RA | 1 |
| Amenta, P | 1 |
| Ettinger, LJ | 1 |
| Sutton, G | 1 |
| Blessing, JA | 3 |
| Malfetano, JH | 1 |
| Hirota, Y | 1 |
| Miyamura, K | 1 |
| Hayata, T | 1 |
| Miyakawa, I | 1 |
| Fetscher, S | 1 |
| Brugger, W | 1 |
| Bertz, H | 1 |
| Krieger, G | 1 |
| Kanz, L | 1 |
| Mertelsmann, R | 1 |
| Lange, W | 1 |
| Gurm, HS | 1 |
| Budd, GT | 1 |
| el Otmany, A | 1 |
| Bouklata, S | 1 |
| Chami, I | 1 |
| Souadka, A | 1 |
| Jahid, A | 1 |
| Belabbas, M | 1 |
| Crowther, D | 1 |
| Rodenhuis, S | 1 |
| Keizer, HJ | 1 |
| Van Hoesel, Q | 1 |
| Frisch, J | 1 |
| Van Oosterom, A | 1 |
| Tursz, T | 1 |
| Kushner, DM | 1 |
| Webster, KD | 1 |
| Belinson, JL | 1 |
| Rybicki, LA | 1 |
| Kennedy, AW | 1 |
| Markman, M | 1 |
| Hadjiliadis, D | 1 |
| Govert, JA | 1 |
| Sutton, GP | 2 |
| Barrett, RJ | 1 |
| McGehee, R | 1 |
| Stornes, I | 1 |
| Mejlholm, I | 1 |
| Jakobsen, A | 1 |
| Photopulos, G | 1 |
| Berman, ML | 1 |
| Homesley, HD | 1 |
| Hawkins, RE | 1 |
| Wiltshaw, E | 1 |
| Mansi, JL | 1 |
| Budach, V | 1 |
| Budach, W | 1 |
| Scheulen, M | 1 |
| Czeglarski, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)[NCT02793050] | 510 participants (Actual) | Observational | 2016-06-15 | Completed | |||
| ATREUS Trial - A Phase II Study on the Activity of Trabectedin of Pretreated Epithelioid or Biphasic / Sarcomatoid Malignant Pleural Mesothelioma(MPM)[NCT02194231] | Phase 2 | 145 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Randomized Phase II Trial Comparing the Activity of trabectedIn vs Gemcitabine in Patients With Metastatic or Locally Advanced Leiomyosarcoma Pretreated With Conventional Chemotherapy[NCT04383119] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-10-29 | Recruiting | ||
| A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153] | Phase 2 | 41 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499] | Phase 2 | 53 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2017-11-06 | Withdrawn (stopped due to No participants enrolled) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for ifosfamide and Leiomyosarcoma
| Article | Year |
|---|---|
Adjuvant chemoradiation for high-grade cardiac leiomyosarcoma in a child: Case report and review of literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Child; Doxo | 2021 |
Eribulin in advanced liposarcoma and leiomyosarcoma.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Furans; Humans; Ifosfamide; Ketones; Leiomyosarcoma; Li | 2017 |
[Hepatic leiomyosarcoma: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Hepatectomy; Hodgkin Disease; H | 2016 |
Long-term survival in metastasized leiomyosarcoma: a case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Disease-Fre | 2015 |
Leiomyosarcoma of the parotid gland in an HIV-positive patient: therapeutic approach, clinical course and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biomar | 2009 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Hu | 2010 |
Leiomyosarcoma of the tongue with multiple metastases: a case report and review of literature.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2012 |
On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality | 2005 |
Myxoid leiomyosarcoma of the uterus.
Topics: Female; Humans; Ifosfamide; Leiomyosarcoma; Middle Aged; Mitotic Index; Uterine Neoplasms | 1993 |
8 trials available for ifosfamide and Leiomyosarcoma
| Article | Year |
|---|---|
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2009 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, | 2009 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, | 2009 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, | 2009 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, | 2009 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, | 2009 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, | 2009 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, | 2009 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, | 2009 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, | 2009 |
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Do | 2013 |
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Disease Progression; Dose-Response Relationship, Dru | 2002 |
Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Gastrointestinal Neo | 1994 |
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu | 2000 |
Gynecologic Oncology Group experience with ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1990 |
36 other studies available for ifosfamide and Leiomyosarcoma
| Article | Year |
|---|---|
Inferior Vena Cava (IVC) Resection Without Reconstruction for a Large IVC Leiomyosarcoma.
Topics: Doxorubicin; Female; Humans; Ifosfamide; Leiomyosarcoma; Middle Aged; Retroperitoneal Neoplasms; Vas | 2022 |
Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report.
Topics: Acetylcysteine; Acute Kidney Injury; Creatinine; Female; Humans; Ifosfamide; Leiomyosarcoma; Mesna; | 2022 |
Neoadjuvant chemotherapy for primary sarcoma of the breast: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Doxorubicin; Female; Humans; Ifosfamide; Lei | 2019 |
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide | 2020 |
Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Leiomy | 2020 |
Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide; Leiomy | 2020 |
Modern multimodality management of patients with caval leiomyosarcoma: New treatment paradigms and potential molecular insights.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dacarbazine; | 2021 |
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxy | 2017 |
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemothera | 2014 |
Favorable control of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma with multimodality therapy: a case report.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Ga | 2014 |
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
Topics: Adenoviridae; Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Survival; Combined Modali | 2015 |
Concomitant aortic leiomyosarcoma and takayasu arteritis in a 55-year-old male patient.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; Combined Modali | 2015 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubic | 2011 |
Novel approaches to treatment of leiomyosarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deox | 2011 |
Response to chemotherapy in a child with primary bronchopulmonary leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Child, Preschool; Dactinomycin; | 2002 |
[Leiomyosarcoma of the heart--interdisciplinary therapeutic approach of systemic chemotherapy and subsequent heart transplantation].
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Heart Atria; He | 2003 |
Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug | 2003 |
Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Bias; Clinical Trials, | 2004 |
Cardiac metastasis from uterine leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidin | 2006 |
Leiomyosarcoma of the left atrium.
Topics: Adult; Antineoplastic Agents, Alkylating; Cardiac Surgical Procedures; Chemotherapy, Adjuvant; Diagn | 2008 |
Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.
Topics: Adult; Cyclophosphamide; Fanconi Syndrome; Female; Humans; Ifosfamide; Intestinal Neoplasms; Leiomyo | 1984 |
[Paraneoplastic peripheral neuropathy in the course of leiomyosarcoma].
Topics: Aged; Combined Modality Therapy; Humans; Ifosfamide; Leiomyosarcoma; Male; Neoplasm Recurrence, Loca | 1995 |
Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; DNA Mutational Analysis; | 1994 |
Successful treatment of a primary cardiac leiomyosarcoma with ifosfamide and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Et | 1996 |
Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; Ifosf | 1997 |
High-dose chemotherapy with autologous peripheral blood stem cell transplantation for metastatic gastric leiomyosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Epiru | 1997 |
A 47-year-old man with leiomyosarcoma and altered mental status.
Topics: Brain Diseases; Fatal Outcome; Humans; Ifosfamide; Leiomyosarcoma; Male; Methylene Blue; Middle Aged | 1999 |
[Primary leiomyosarcoma of the kidney. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Kidn | 1999 |
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; | 2000 |
Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Diagnosis, Differential; Female; Humans; Ifosfamide; | 2000 |
Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Agranulocytosis; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide | 1992 |
Chemotherapy in perineal leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; H | 1992 |
Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Leio | 1990 |
Primary chemosensitivity and secondary drug resistance of xenografted soft part sarcomas.
Topics: Animals; Bleomycin; Doxorubicin; Drug Resistance; Female; Histiocytoma, Benign Fibrous; Humans; Ifos | 1989 |